To conclude, there is a strong rationale for targeting Tregs using low doses of IL-2 to treat autoimmune diseases given the evidence from GWAS studies, mechanistic in vitro Treg studies, and experiments in animal models. This evidence concerns the gene IL2 and autoimmune disease.